During the corresponding time, Durect Corp saw a revenue deteriorated by -79.41 % year on year, sequentially revenue grew by 39.25 %. While revenue at the Durect Corp's corporate clients
Durect's Comment on Sales, Marketing and Customers
The company's product revenues primarily derive from the sale of key excipients used in POSIMIR, Methydur Sustained Release Capsules, and other products. These sales are expected to remain the principal revenue source until pharmaceutical product candidates are commercialized. Additional revenue is generated from collaborative research and development arrangements and earn-out revenue from a patent purchase agreement. In 2024, Indivior accounted for 78% of the company's total revenue. Manufacturing pharmaceutical product candidates involves complex processes requiring qualified facilities. The company has entered into manufacturing agreements with third parties for larsucosterol and POSIMIR, with the POSIMIR agreement currently assigned to Innocoll through May 6, 2025. The company operates a small manufacturing facility in California for research and clinical supplies and produces certain key components for POSIMIR and Methydur at this site. The company may expand manufacturing capabilities or engage third-party manufacturers in the future to meet demand.
Durect’s Comment on Sales, Marketing and Customers
The company's product revenues primarily derive from the sale of key excipients used in POSIMIR, Methydur Sustained Release Capsules, and other products. These sales are expected to remain the principal revenue source until pharmaceutical product candidates are commercialized. Additional revenue is generated from collaborative research and development arrangements and earn-out revenue from a patent purchase agreement. In 2024, Indivior accounted for 78% of the company's total revenue. Manufacturing pharmaceutical product candidates involves complex processes requiring qualified facilities. The company has entered into manufacturing agreements with third parties for larsucosterol and POSIMIR, with the POSIMIR agreement currently assigned to Innocoll through May 6, 2025. The company operates a small manufacturing facility in California for research and clinical supplies and produces certain key components for POSIMIR and Methydur at this site. The company may expand manufacturing capabilities or engage third-party manufacturers in the future to meet demand.
Sources:
Durect Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Durect Corp’s corporate clients.
For your research, we’ve provided 9 tables on Durect Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
72.48 %